Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356745 | 1.00 | TYR (0.51) | TYRMMP2LMNAKDM4ECYP3A4 | |
| SCHEMBL3642353 | 0.78 | TUBB1 (0.50) | MMP2KDM4ECYP3A4TP53ALDH1A1 | |
| SCHEMBL3642356 | 0.78 | TUBB1 (0.50) | MMP2KDM4ECYP3A4TP53ALDH1A1 | |
| SCHEMBL2119058 | 0.77 | TYR (0.65) | TYRLMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL21852875 | 0.77 | TYR (0.65) | TYRLMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL30491036 | 0.77 | TYR (0.65) | TYRLMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL10602315 | 0.77 | TYR (0.65) | TYRLMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL7546943 | 0.75 | TUBB1 (0.55) | TYRTUBB1CNR2NQO2ALOX5 | |
| SCHEMBL7546946 | 0.75 | TUBB1 (0.55) | TYRTUBB1CNR2NQO2ALOX5 | |
| SCHEMBL21110872 | 0.75 | LMNA (0.70) | TYRLMNAKDM4ECYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-09-24 | — | — | US | claimed |
| US-8183405-B2 | Obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-05-22 | — | — | US | disclosed |
| US-8183405-B2 | Obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-05-22 | — | — | US | disclosed |
| US-8183405-B2 | Obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-05-22 | — | — | US | disclosed |
| US-20100125103-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES | TG BIOTECH CO. LTD. (KR) | 2010-05-20 | — | — | US | disclosed |
| US-20100125103-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES | TG BIOTECH CO. LTD. (KR) | 2010-05-20 | — | — | US | disclosed |
| US-20100125103-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES | TG BIOTECH CO. LTD. (KR) | 2010-05-20 | — | — | US | disclosed |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-09-24 | — | — | US | disclosed |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-09-24 | — | — | US | disclosed |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125103-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES | GPR119, PRKAG1, AK1 | TYR 1780/4885MMP2 3067/4885LMNA 4162/4885 |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | OGFRL1, TP53, BAX | TYR 258/4885MMP2 640/4885LMNA 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.